NCT06440993招募中2 期
The CLEAN-DUCT / TRITICC-3 Trial - Phase IIa, Prospective, Single Arm, Open Label, Non-randomized, Multi-center Pilot Study of Durvalumab (MEDI4736) + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest10 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2024年8月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 42
- 试验地点
- 10
- 主要终点
- Overall survival rate
研究概览
简要总结
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled.
We hypothesize that in patients with extrahepatic cholangiocarcinoma, the use of a combination radiofrequency ablation followed by systemic treatment with chemotherapy plus durvalumab might further increase the anti-tumor activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient* has given written informed consent.
- •Patient is ≥ 18 years of age at time of signing the written informed consent.
- •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •Patient has been diagnosed with histologically or cytologically confirmed
- •histologically or cytologically confirmed cholangiocarcinoma as adenocarcinoma of pancreatobiliary type
- •unresectable perihilar and/or ductal cholangiocarcinoma with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT) and already resolved cholestasis due to RFA + stent
- •Patient tolerated RFA prior to inclusion and is eligible for repeat RFA during the study (does not have any contraindications) as determined by investigator.
- •Patient is eligible for palliative systemic therapy based on clinical and laboratory parameters (except hyperbilirubinemia) as determined by the local MDT
- •Patient has a ECOG ≤
- •Patient has life expectancy of ≥ 12 weeks
- •Patient has body weight > 30 kg
- •Adequate blood count, liver-enzymes, and renal function:
- •ANC > 1,500 cells/μL without the use of hematopoietic growth factors
- •Platelet count ≥ 100 x 109/L (>100,000 per mm3)
- •Hemoglobin ≥ 9 g/dL
- •Serum total bilirubin ≤ 3x upper normal limit (ULN) (biliary drainage is allowed for biliary obstruction; elevated bilirubin should be caused by obstruction not impaired liver function as assessed by albumin and INR values)
- •Albumin levels ≥ 2.8 g/dL
- •Patients not receiving therapeutic anticoagulation must have an INR< 2.0 ULN and PTT < 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of inclusion
- •AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN
- •Serum Creatinine ≤ 1.5 x ULN and a calculated creatinine clearance rate ≥ 60 mL /min
- •Female patients defined as women of childbearing potential (WOCBP) or male patients with WOCBP partners must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of chemotherapy or for at least 3 months after last dose of durvalumab, whatever happens last. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.
排除标准
- •Patient received previous or simultaneous endobiliary treatment other than RFA (e.g. PDT or brachytherapy)
- •Patient received previous systemic therapy with a PD-1, PD-L1 inhibitor (including durvalumab) or CTLA4 inhibitor or classical chemotherapy agents like platinum, fluoropyrimidine or gemcitabine-based regimens.
- •Patient receives any concurrent chemotherapy, investigational product or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (e.g., hormone replace therapy) is acceptable.
- •Patient has known hypersensitivity to any component of the durvalumab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein and/or any known contraindication (including hypersensitivity) to gemcitabine or cisplatin.
- •Patient has history of primary immunodeficiency
- •Patient has stage B cirrhosis according to Child-Pugh criteria (or worse) or cirrhosis (of any grade) with a history of hepatic encephalopathy or clinically significant ascites resulting from cirrhosis. Clinically significant ascites is defined as ascites resulting from cirrhosis requiring diuretics or paracentesis.
- •Patient has any unresolved NCI CTCAE grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and laboratory values defined in the inclusion criteria
- •Patients with grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Lead Investigator
- •Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Lead Investigator.
- •Patient had a prior allogeneic bone marrow transplantation or prior solid organ transplantation.
- •Patient has active or history of autoimmune or inflammatory disorders (including, but not limited to, inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis]) . The following are exceptions:
- •Patients with vitiligo or alopecia
- •Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement
- •Patients with any chronic skin condition that does not require systemic therapy
- •Patients with celiac disease controlled by diet alone
- •Patients without active disease in the last 5 years may be included but only after consultation with the Lead Investigator
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
研究组 & 干预措施
systemic plus ID-RFA
Experimental
systemic treatment: - combination treatment for 8 cycles (Q3W):
- Gemcitabine, 1,000 mg/m2 IV, on day 1 and 8,
- Cisplatin, 25 mg/m2 IV, on day 1 and 8
- Durvalumab, 1,500 mg IV, on day 1 followed by
- Durvalumab maintenance, 1,500 mg IV, PLUS • 2 endoscopic intraductal RFA
干预措施: Gemcitabine (Drug)
systemic plus ID-RFA
Experimental
systemic treatment: - combination treatment for 8 cycles (Q3W):
- Gemcitabine, 1,000 mg/m2 IV, on day 1 and 8,
- Cisplatin, 25 mg/m2 IV, on day 1 and 8
- Durvalumab, 1,500 mg IV, on day 1 followed by
- Durvalumab maintenance, 1,500 mg IV, PLUS • 2 endoscopic intraductal RFA
干预措施: Cisplatin (Drug)
systemic plus ID-RFA
Experimental
systemic treatment: - combination treatment for 8 cycles (Q3W):
- Gemcitabine, 1,000 mg/m2 IV, on day 1 and 8,
- Cisplatin, 25 mg/m2 IV, on day 1 and 8
- Durvalumab, 1,500 mg IV, on day 1 followed by
- Durvalumab maintenance, 1,500 mg IV, PLUS • 2 endoscopic intraductal RFA
干预措施: Durvalumab (Drug)
systemic plus ID-RFA
Experimental
systemic treatment: - combination treatment for 8 cycles (Q3W):
- Gemcitabine, 1,000 mg/m2 IV, on day 1 and 8,
- Cisplatin, 25 mg/m2 IV, on day 1 and 8
- Durvalumab, 1,500 mg IV, on day 1 followed by
- Durvalumab maintenance, 1,500 mg IV, PLUS • 2 endoscopic intraductal RFA
干预措施: ID-RFA (Procedure)
结局指标
主要结局
Overall survival rate
时间窗: at 12 months
Overall survival rate after 12 months (OS@12months) defined as proportion of patients alive 12 months after enrollment
次要结局
- Overall survival (OS)(at study end)
- Incidence and nature of adverse events using NCI CTCAE 5.0(through study completion, up to 3years)
- To assess quality of life (QoL) data from patients using EORTC QLQ-C30(through study completion, up to 3years)
- Progression-free survival (PFS)(at study end)
- Time to cholangitis(from enrollment to first cholangitis event, up to 3 years)
- To assess quality of life (QoL) data from patients using EORTC QLQ-BIL21(through study completion, up to 3years)
研究者
研究点 (10)
Loading locations...
相似试验
终止
2 期
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerTriple Negative Breast CancerNCT05113966G1 Therapeutics, Inc.30
招募中
2 期
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerEndometrial CancerNCT06463028Faeth Therapeutics40
已完成
1 期
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaMultiple Myeloma in RelapseNCT03136653Molecular Partners AG33
招募中
2 期
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALLRelapsed B Acute Lymphoblastic LeukaemiaRefractory B Acute Lymphoblastic LeukaemiaNCT03937544National University of Malaysia10
已完成
3 期
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With InhibitorsHemophilia ANCT03191799Hoffmann-La Roche195